Ibnsina Pharma (CAI:ISPH) Construction In Progress: E£1,096 Mil (As of Mar. 2026)


CAI:ISPH Ibnsina Pharma CAI:ISPH
85 GF Score
Price E£11.60
GF Value E£10.48
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ibnsina Pharma Construction In Progress?

Ibnsina Pharma CAI:ISPH -0.60% 85 Construction In Progress is E£1,096 Mil as of Mar. 2026. GuruFocus rates CAI:ISPH with a GF Score™ of 85/100 and a GF Value™ of E£10.48 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Ibnsina Pharma's quarterly construction in progress increased from Sep. 2025 (E£275 Mil) to Dec. 2025 (E£832 Mil) and increased from Dec. 2025 (E£832 Mil) to Mar. 2026 (E£1,096 Mil).

Ibnsina Pharma's annual construction in progress declined from Dec. 2023 (E£428 Mil) to Dec. 2024 (E£211 Mil) but then increased from Dec. 2024 (E£211 Mil) to Dec. 2025 (E£832 Mil).

Ibnsina Pharma Construction In Progress Historical Data

* Premium members only.

The historical data trend for Ibnsina Pharma's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ibnsina Pharma Construction In Progress Chart

Ibnsina Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 242.88 944.82 427.51 210.77 832.14

Ibnsina Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 175.68 205.34 275.43 832.14 1,096.37
CAI:ISPH
85GF Score
Ibnsina Pharma CAI:ISPH
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ibnsina Pharma Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of E£1,096 Mil mean?
Ibnsina Pharma (CAI:ISPH) has a Construction In Progress of E£1,096 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Ibnsina Pharma and its competitors.
Is Ibnsina Pharma's Construction In Progress too high?
Ibnsina Pharma's current Construction In Progress is E£1,096 Mil. Overall, Ibnsina Pharma has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's Construction In Progress compare to MCK and CAH?
Ibnsina Pharma's Construction In Progress of E£1,096 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Medical Distribution company?
A good Construction In Progress depends on the Medical Distribution industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Ibnsina Pharma and its competitors. Ibnsina Pharma's current Construction In Progress is E£1,096 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£10.48, compared to a current price of E£11.60 — trading 10.7% above its estimated fair value. The current Construction In Progress is E£1,096 Mil. Ibnsina Pharma's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current Construction In Progress is E£1,096 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?

Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued. The current stock price of E£11.60 is trading 10.7% above its estimated GF Value™ of E£10.48. GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.

Key valuation signals for CAI:ISPH:

  • Construction In Progress: E£1,096 Mil
  • GF Value™: E£10.48 vs. price of E£11.60 (10.7% above fair value)
  • GF Score™: 85/100 with 7 warning signs

No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ibnsina Pharma Business Description

Address Industrial zone 1, PO box 91, Obour, EGY
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
85GF Score

Get the complete analysis for CAI:ISPH

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£11.60
Price
E£10.48
GF Value